☆ 4.6 Article

The successful combination of grapefruit juice and venetoclax in an unfit acute myeloid leukemia patient with adverse risk: A case report

FRONTIERS IN ONCOLOGY (2022)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Immunology

Comparison of Mold Active Triazoles as Primary Antifungal Prophylaxis in Patients With Newly Diagnosed Acute Myeloid Leukemia in the Era of Molecularly Targeted Therapies

Caitlin R. Rausch et al.

Summary: The rate of breakthrough invasive fungal infections (bIFI) during remission induction chemotherapy was low (4%) in newly diagnosed AML patients receiving mold-active triazole antifungals for primary antifungal prophylaxis (PAP). Lower complete remission rate was observed in patients with bIFI. The rate of bIFI was comparable among different PAP agents and chemotherapy intensities.

CLINICAL INFECTIOUS DISEASES (2022)

添加到收藏夹

Article Oncology

Venetoclax in combination with hypomethylating agents or low dose cytarabine for relapsed and refractory acute myeloid leukemia

Molly E. Graveno et al.

Summary: This retrospective analysis shows that Venetoclax combination therapy is efficacious in patients with relapsed/refractory acute myeloid leukemia (AML), leading to improved overall survival (OS) and progression-free survival (PFS). These findings suggest the need for further prospective studies on this treatment approach.

LEUKEMIA & LYMPHOMA (2022)

添加到收藏夹

Article Oncology

Venetoclax in combination with hypomethylating agents in previously untreated patients with acute myeloid leukemia ineligible for intensive treatment: a real-life multicenter experience

Eleonora De Bellis et al.

Summary: This study retrospectively evaluated the outcomes of 56 newly diagnosed AML patients ineligible for intensive treatment who received HMA-V therapy. The results showed that HMA-V treatment achieved good response rates in these patients, with a median overall survival of 12.3 months.

LEUKEMIA RESEARCH (2022)

添加到收藏夹

Article Oncology

Eprenetapopt Plus Azacitidine in TP53-Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Phase II Study by the Groupe Francophone des Myelodysplasies (GFM)

Thomas Cluzeau et al.

Summary: The combination of Eprenetapopt with AZA showed potentially higher overall response rate (ORR) and complete remission (CR) rate, as well as longer overall survival (OS) in untreated high-risk TP53m MDS and AML patients, with main treatment-related adverse events being febrile neutropenia and neurologic adverse events.

JOURNAL OF CLINICAL ONCOLOGY (2021)

添加到收藏夹

Article Hematology

Cost-effectiveness of azacitidine and venetoclax in unfit patients with previously untreated acute myeloid leukemia

Kishan K. Patel et al.

Summary: The combination therapy of azacitidine-venetoclax shows improved survival rates for previously untreated AML patients but is deemed cost-ineffective due to significantly higher healthcare costs. Further reduction in the price of venetoclax is necessary to make it a more cost-effective treatment option.

BLOOD ADVANCES (2021)

添加到收藏夹

Article Hematology

Intact TP-53 function is essential for sustaining durable responses to BH3-mimetic drugs in leukemias

Rachel Thijssen et al.

Summary: Selective targeting of BCL-2 with BH3-mimetic venetoclax has shown promising results in treating various leukemias. However, for patients with TP53 mutations, a combined BH3-mimetic approach targeting both BCL-2 and MCL-1 proves to be more effective in suppressing leukemia burden. It is crucial to use sufficiently lethal treatment strategies to maximize outcomes for patients with TP53-mutant disease and to avoid the risk of disease progression driven by emergent TP53-mutant clones.

BLOOD (2021)

添加到收藏夹

Article Oncology

Duration of cytopenias with concomitant venetoclax and azole antifungals in acute myeloid leukemia

Caitlin R. Rausch et al.

Summary: Venetoclax combined with a hypomethylating agent has shown improved survival in elderly AML patients, but can lead to prolonged neutropenia and thrombocytopenia when combined with azole antifungals. Recovery times for neutrophils and platelets were similar in patients receiving azoles, but significantly longer for platelet recovery. Posaconazole and voriconazole did not significantly impact recovery times, suggesting safety of these combinations during treatment.

CANCER (2021)

添加到收藏夹

Article Oncology

Duration of cytopenias with concomitant venetoclax and azole antifungals in acute myeloid leukemia

Caitlin R. Rausch et al.

Summary: Background: Venetoclax combined with HMA improves survival in elderly patients with AML. However, this treatment can lead to profound neutropenia, requiring antifungal prophylaxis. Limited data exist on the outcomes of patients receiving VEN, HMA, and azoles.

CANCER (2021)

添加到收藏夹

Article Hematology

How I treat acute myeloid leukemia in the era of new drugs

Courtney D. DiNardo et al.

BLOOD (2020)

添加到收藏夹

Review Hematology

Drug-drug interactions of newly approved small molecule inhibitors for acute myeloid leukemia

Juan Eduardo Megias-Vericat et al.

ANNALS OF HEMATOLOGY (2020)

添加到收藏夹

Article Medicine, General & Internal

Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia

C. D. DiNardo et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

添加到收藏夹

Article Oncology

Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study

Andrew H. Wei et al.

JOURNAL OF CLINICAL ONCOLOGY (2019)

添加到收藏夹

Article Oncology

How we use venetoclax with hypomethylating agents for the treatment of newly diagnosed patients with acute myeloid leukemia

Brian A. Jonas et al.

LEUKEMIA (2019)

添加到收藏夹

Article Hematology

Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia

Courtney D. DiNardo et al.

BLOOD (2019)

添加到收藏夹

Article Hematology

Invasive fungal infections in acute myeloid leukemia treated with venetoclax and hypomethylating agents

Ibrahim Aldoss et al.

BLOOD ADVANCES (2019)

添加到收藏夹

Article Hematology

Venetoclax for AML: changing the treatment paradigm

Daniel A. Pollyea et al.

BLOOD ADVANCES (2019)

添加到收藏夹

Article Oncology

Enhancing venetoclax activity in acute myeloid leukemia by co-targeting MCL1

T-C Teh et al.

LEUKEMIA (2018)

添加到收藏夹

Review Food Science & Technology

Food-drug interactions precipitated by fruit juices other than grapefruit juice: An update review

Meng Chen et al.

JOURNAL OF FOOD AND DRUG ANALYSIS (2018)

添加到收藏夹

Article Oncology

Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study

Courtney L. DiNardo et al.

LANCET ONCOLOGY (2018)

添加到收藏夹

Article Oncology

Relationship between venetoclax exposure, rituximab coadministration, and progression-free survival in patients with relapsed or refractory chronic lymphocytic leukemia: demonstration of synergy

Kevin J. Freise et al.

HEMATOLOGICAL ONCOLOGY (2017)

添加到收藏夹

Article Pharmacology & Pharmacy

Pharmacokinetics of Venetoclax, a Novel BCL-2 Inhibitor, in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Non-Hodgkin Lymphoma

Ahmed Hamed Salem et al.

JOURNAL OF CLINICAL PHARMACOLOGY (2017)

添加到收藏夹

Article Pharmacology & Pharmacy

Quantitative Prediction of the Effect of CYP3A Inhibitors and Inducers on Venetoclax Pharmacokinetics Using a Physiologically Based Pharmacokinetic Model

Kevin J. Freise et al.

JOURNAL OF CLINICAL PHARMACOLOGY (2017)

添加到收藏夹

Article Pharmacology & Pharmacy

Management of Venetoclax-Posaconazole Interaction in Acute Myeloid Leukemia Patients: Evaluation of Dose Adjustments

Suresh K. Agarwal et al.

CLINICAL THERAPEUTICS (2017)

添加到收藏夹

Review Pharmacology & Pharmacy

Fruit Juices as Perpetrators of Drug Interactions: The Role of Organic Anion-Transporting Polypeptides

M. J. Dolton et al.

CLINICAL PHARMACOLOGY & THERAPEUTICS (2012)

添加到收藏夹

Article Biochemistry & Molecular Biology

Mutant p53 Protein Is Targeted by Arsenic for Degradation and Plays a Role in Arsenic-mediated Growth Suppression

Wensheng Yan et al.

JOURNAL OF BIOLOGICAL CHEMISTRY (2011)

添加到收藏夹

Article Medicine, General & Internal

Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia

Oliver A. Cornely et al.

NEW ENGLAND JOURNAL OF MEDICINE (2007)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.